Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Background:
- On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In addition, Metsera stockholders could receive a non-tradable CVR to receive certain contingent payments in cash upon achievement of specified milestones.
- The merger consideration is significantly below Wall Street analyst projections, with an average estimate of $63.50 and a high of $77.00.
If you own Metsera shares and believe this proposed deal grossly undervalues your investment, please consider joining our investigation.
If you are a shareholder of Metsera and interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.